


# Embosphere<sup>®</sup>

Microspheres



Predictable. Targeted. Established.™

# Embosphere®

## Microspheres

### PREDICTABLE

Embosphere Microspheres temporarily compress up to 33% for smooth microcatheter passage. Once through the microcatheter, they return to their original spherical shape and stated diameter for predictable, reliable delivery.<sup>1</sup>

### TARGETED

Embosphere Microspheres show a direct correlation between the level of arterial occlusion and the size of the particles used, allowing for consistent and reliable targeted occlusion.<sup>2,3</sup>

### ESTABLISHED

Embosphere Microspheres are the most clinically studied and clinically utilised spherical embolic, having been proven:

- In over 350,000 procedures<sup>4</sup>
- With +20 years' clinical experience<sup>4</sup>
- In more than 200 clinical articles<sup>4</sup>





### Non-Aggregating Properties

The hydrophilic surface and spherical shape of Embosphere Microspheres prevent aggregation in the catheter lumen and vasculature.

### Superior Rebound Capability


Embosphere Microspheres' elastic properties allow temporary compression of up to 33% to facilitate smooth microcatheter passage (A).<sup>1</sup> Once through the microcatheter, Embosphere Microspheres return to their original spherical shape and stated diameter (B) for predictable, targeted delivery.<sup>1</sup>





## Durable Occlusion


Embosphere Microspheres are biocompatible and nonresorbable with cell adhesion properties that enable complete and durable mechanical occlusion.



Embosphere Microspheres at six months (A) and six years (B) after embolisation of facial AVM.

Images courtesy of Dr. Alex Laurent, Hôpital Lariboisière, Paris, France

## Percentage of Patients with Complete Infarction Rates of Overall Uterine Fibroid Tumor Burden



With Embosphere Microspheres, **92.3% of patients experienced 100% infarction** of their entire uterine fibroid tumor burden.

Complete infarction of all fibroids leads to better long-term clinical outcomes, including a higher rate of symptom control and a lower rate of additional gynecologic intervention compared with incomplete infarction of fibroid tissue.<sup>8</sup>

### REFERENCES

1. Laurent, et al. Trisacryl Gelatin Microspheres for Therapeutic Embolization, I: Development and In Vitro Evaluation. *Am J Neuroradiol.* 1996 Mar; 17:533-540
2. Pelage JP, et al. Uterine Artery Embolization in Sheep: Comparison of Acute Effects with Polyvinyl Alcohol Particles and Calibrated Microspheres. *Radiol.* 2002;224:436-45
3. Verret V, et al. The Arterial Distribution of Embozene and Embosphere Microspheres in Sheep Kidney and Uterus Embolization Models. *J Vasc Interv Radiol.* 2011 Feb;22(2):220-8
4. Data on file
5. Siskin G, et al. Leiomyoma Infarction after Uterine Artery Embolization: A Prospective Randomized Study Comparing Tris-acryl Gelatin Microspheres versus Polyvinyl Alcohol Microspheres. *J Vasc Interv Radiol.* 2008; 19:42-46
6. Smeets AJ, et al. Embolization of Uterine Leiomyomas with Polyzene F-coated Hydrogel Microspheres: Initial Experience. *J Vasc Interv Radiol.* 2010 Dec;21(12):1830-4
7. Chrisman HB, et al., Prospective Evaluation of the Embolic Agent Bead Block in the Treatment of Uterine Leiomyomas with Uterine Artery Embolization. *J Vasc Interv Radiol.* 2010 Apr;21(4):484-9
8. Katsumori T, et al. Infarction of Uterine Fibroids After Embolization: Relationship Between Postprocedural Enhanced MRI Findings and Long-Term Clinical Outcomes. *Cardiovasc Intervent Radiol.* 2008;31:66

# Embosphere®

## Microspheres

### ORDERING INFORMATION

SYRINGES

Syringe Size Range (µm)	Colour Code	1 mL Syringe Product Number	2 mL Syringe Product Number
50-100	Gray	--	S020GH
40-120	Orange	--	S120GH
100-300	Yellow	S210GH	S220GH
300-500	Blue	S410GH	S420GH
500-700	Red	S610GH	S620GH
700-900	Green	S810GH	S820GH
900-1200	Purple	S1010GH	S1020GH

Embosphere Microspheres supplied in sterile saline in 20 mL syringe. Sold 1 per box.



### SPECIFIC SIZE RANGES

Embosphere Microspheres are available in seven specific size ranges to achieve predictable and efficient vessel occlusion.

### USAGE INSTRUCTIONS

#### Suspension

1. Inject an equivalent amount of CM to the NaCl provided in the syringe (50/50).
2. Spheres will begin to float after the injection.
3. Gently invert the syringe, after 3 minutes you will get a durable suspension.



#### Indications For Use

Embosphere Microspheres are designed to occlude blood vessels, for therapeutic or preoperative purposes, in the following procedures:

- Embolisation of hypervascular tumours and processes, including uterine fibroids, meningiomas, liver tumours.
- Embolisation of the prostate arteries for relief of symptoms related to Benign Prostatic Hyperplasia.
- Embolisation of arteriovenous malformations.
- Haemostatic embolisation.



Biosphere Medical, S.A.  
Parc des Nations - Paris Nord 2  
383 rue de la Belle Etoile  
95700 Roissy en France

France



The above suggestions and other information are for the practitioner's convenience and for general information purposes only. This information does not constitute medical or legal advice, nor is it meant to endorse or guarantee the suitability of any of the referenced products or methods for any specific patient or procedure. Before using any product, refer to the Instructions for Use (IFU) for indications, contraindications, warnings, precautions, and directions for use.



Understand. Innovate. Deliver.™

merit.com

Merit Medical Systems, Inc.  
1600 West Merit Parkway  
South Jordan, Utah 84095  
1.801.253.1600  
1.800.35.MERIT

Merit Medical Europe, Middle  
East, & Africa (EMEA)  
Amerikalaan 42, 6199 AE  
Maastricht-Airport  
The Netherlands  
+31 43 358 82 22

Merit Medical Ireland Ltd.  
Parkmore Business Park West  
Galway, Ireland  
+1800 553163